EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML

Carolin S Joisten iD, Sibylle C Mellinghoff iD, Danila Seidel iD, Carsten Müller iD, Charlotte Müller-Ohrem iD, Karl-Anton Kreuzer, Lukas P Frenzel iD, Florian Simon iD, Michael Hallek iD, Philipp Koehler iD, Oliver A Cornely iD, Jannik Stemler iD

Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)

DOI: 10.1128/aac.01951-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Carolin S Joisten und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology (CIO), Medical Faculty and University Hospital of Cologne, University of Cologne, C…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Staurosporine, fms-Like Tyrosine Kinase 3, Triazoles. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty of the University Hospital of Cologne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To determine midostaurin and posaconazole plasma concentrations and investigate adverse events (AEs) resembling drug-drug interactions (DDI) when both drugs were administered concomitantly during induction chemotherapy for acute myeloid leukemia (AML). Patients with FLT3-mutated AML who received midostaurin and posaconazole concomitantly between May 2019 and December 2022 were included and followed up to March 2023. Twice-weekly trough levels for midostaurin and posaconazole were measured with validated liquid chromatography–tandem mass spectrometry methods. Potential DDIs were independently reviewed by two physicians and attributed using the Drug Interaction Probability Scale (DIPS). Population pharmacokinetics analysis was done via nonlinear mixed-effect modeling. In 29 patients, concentrations ranged from 0.6 to 24.5 mg/L for midostaurin and from

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteStaurosporinefms-Like Tyrosine Kinase 3TriazolesAntifungal AgentsHumansDrug InteractionsFemaleMiddle AgedMaleAgedAdultMutation

Stichwörter der Autor:innen

adverse effectsantifungal prophylaxisaspergillosiscytochrome p450leukemiamucormycosistargeted therapytherapeutic drug monitoring

Substanzen

posaconazolemidostaurinStaurosporinefms-Like Tyrosine Kinase 3TriazolesAntifungal AgentsFLT3 protein, human

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology (CIO), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Ger…
  • German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • TDM Laboratory, Center for Laboratory Diagnostics, University Hospital of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Division of Clinical Immunology, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Clinical Trials Center Cologne (ZKS Köln), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

ORCID-Profile: Carolin S Joisten, Sibylle C Mellinghoff, Danila Seidel, Carsten Müller, Charlotte Müller-Ohrem, Lukas P Frenzel, Florian Simon, Michael Hallek, Philipp Koehler, Oliver A Cornely, Jannik Stemler

Förderung

  • Medical Faculty of the University Hospital of Cologne

Zitieren

APA

Joisten, C. S., Mellinghoff, S. C., Seidel, D., Müller, C., Müller-Ohrem, C., Kreuzer, K. A., Frenzel, L. P., Simon, F., Hallek, M., Koehler, P., Cornely, O. A., & Stemler, J. (2026). Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01951-25

Vancouver

Joisten CS, Mellinghoff SC, Seidel D, Müller C, Müller-Ohrem C, Kreuzer KA, et al. Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01951-25

BibTeX
@article{Joisten2026,
  author = {Joisten, Carolin S and Mellinghoff, Sibylle C and Seidel, Danila and Müller, Carsten and Müller-Ohrem, Charlotte and Kreuzer, Karl-Anton and Frenzel, Lukas P and Simon, Florian and Hallek, Michael and Koehler, Philipp and Cornely, Oliver A and Stemler, Jannik},
  title = {Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {6},
  doi = {10.1128/aac.01951-25}
}
Kostenlos starten →